The United States liquid biopsy market is anticipated to grow at an impressive CAGR for the forecast period, 2023-2027. Rising preference for non-invasive treatment procedures and increasing incidence and prevalence of cancer are the primary factors driving the demand for the United States liquid biopsy market in the forecast period.

Increasing Prevalence of Cancer Drives the Market Growth

Rise in tobacco consumption, lifestyle changes and environmental factors, and contamination with infectious agents such as Hepatitis B and C are some of the factors causing cancer in a large number of individuals. According to WHO, cancer is considered one of the leading causes of death of patients at the global level. Liquid biopsy is in high demand among healthcare professionals for cancer treatment as it is highly effective compared to traditional cancer diagnostics techniques. Liquid biopsy offers several advantages such as increased patient comfort, acquired drug resistance, lower cost, therapy monitoring, early prognosis, and detection of tumor heterogeneity over traditional treatment methods.

Rise In Awareness About Non-Invasive Treatment Method Boosts Market Growth

Liquid biopsy has revolutionized cancer treatment as it is a simple and non-invasive treatment and provides a better alternative to invasive surgical biopsies. It helps the healthcare professionals to discover a plethora of information about the tumor through a simple sample. The method is quick and provides real-time information about the current condition.

At present, liquid biopsy treatment includes circulating tumor DNA (ctDNA), circulating tumor cells (CTC), and exosomes for which the samples can be taken through blood, saliva, urine of the patient. The non-invasive nature of liquid biopsy is the main reason for its high demand among healthcare professionals. It requires only 5 milliliters of blood, making the process tolerable, convenient, and quicker for the patients than the invasive methods. One of the significant advantages of liquid biopsy is it can detect treatment resistance or disease progression beforehand than it appears on imaging scans or shows clinical symptoms.

High Demand for Companion Diagnostics Supports The Market Growth

Companion diagnostics include tests or assays, which play a crucial role in providing cancer patients with information to determine the effective and safe use of the biological product or corresponding drug. Healthcare providers can compare the benefits of the drug, which should ideally outweigh the potential side-effect or risks for the patient.

Companion diagnostics can optimize and improve the drug development process by helping in the identification of safer drugs having higher therapeutic efficacy. They minimize the chances of error and make the drugs affordable and the drug production process more cost-effective. The demand for quality treatment and effective drugs boosts the adoption of companion diagnostics by drug manufacturers and research and diagnostic centers. High penetration of companion diagnostics due to growing awareness about the advantages of the process is expected to support the growth of the United States liquid biopsy market throughout the forecast period.


Click here to download the sample

Market Segmentation

The United States liquid biopsy market is divided into product & services, circulating biomarker, technology, application, end user, regional distribution, and company. Based on the product & services, the market is divided into assay kits, instruments, services. Based on the circulating biomarker, the market is divided into circulating tumor cells, circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and others.

Based on the technology, the market is divided into multi-gene parallel analysis using NGS and single-gene analysis using PCR microarrays. Based on application, the market is divided into cancer and non-cancer. Based on the end user, the market is divided into hospitals & clinics, reference laboratories, others. To analyze the market based on the region, the United States liquid biopsy market is studied in major regions namely Southern region, Western region, Mid-Western region, and North-Eastern region.

Market Players

Thermo Fischer Scientific, Inc., Guardant Health, Inc., Biocept, Inc., Roche Diagnostics Corporation, Myriad Genetics, Inc., Exact Sciences Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Personal Genome Diagnostics, Inc., are among the major market players operating in the United States liquid biopsy market.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Product & Services

·         Circulating Biomarker

·         Technology

·         Application

·         End User

Regional scope

South, West, Mid-West, North-East

Key companies profiled

Thermo Fischer Scientific, Inc., Guardant Health, Inc., Biocept, Inc., Roche Diagnostics Corporation, Myriad Genetics, Inc., Exact Sciences Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Personal Genome Diagnostics, Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, United States liquid biopsy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • United States Liquid Biopsy Market, By Product & Services:
    • Assay Kits
    • Instruments
    • Services
  • United States Liquid Biopsy Market, By Circulating Biomarker:
    • Circulating Tumor Cells
    • Circulating Tumor DNA (ctDNA)
    • Cell-free DNA (cfDNA)
    • Others
  • United States Liquid Biopsy Market, By Technology:
    • Multi-gene Parallel Analysis using NGS
    • Single-gene Analysis using PCR Microarrays
  • United States Liquid Biopsy Market, By Application:
    • Cancer
    • Non-Cancer
  • United States Liquid Biopsy Market, By End User:
    • Hospitals & Clinics
    • Reference Laboratories
    • Others
  • United States Liquid Biopsy Market, By Region:
    • South
    • West
    • Mid-West
    • North-East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States liquid biopsy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

United States liquid biopsy market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on United States Liquid Biopsy Market

4.    Voice of Customer

5.    Executive Summary

6.    United States Liquid Biopsy Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Product & Services (Assay Kits, Instruments, Services)

6.2.2.     By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others)

6.2.3.     By Technology (Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR Microarrays)

6.2.4.     By Application (Cancer v/s Non-Cancer)

6.2.5.     By End User (Hospitals & Clinics, Reference Laboratories, Others)

6.2.6.     By Company (2021)

6.2.7.     By Region

6.3.  Product Market Map

7.    North-East Liquid Biopsy Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Product & Services

7.2.2.     By Circulating Biomarker

7.2.3.     By Technology

7.2.4.     By Application

7.2.5.     By End User

8.    North-East Liquid Biopsy Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Product & Services

8.2.2.     By Circulating Biomarker

8.2.3.     By Technology

8.2.4.     By Application

8.2.5.     By End User

9.    Mid-West Liquid Biopsy Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Product & Services

9.2.2.     By Circulating Biomarker

9.2.3.     By Technology

9.2.4.     By Application

9.2.5.     By End User

10.  West Liquid Biopsy Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Product & Services

10.2.2.  By Circulating Biomarker

10.2.3.  By Technology

10.2.4.  By Application

10.2.5.  By End User

11.  South Liquid Biopsy Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Product & Services

11.2.2.  By Circulating Biomarker

11.2.3.  By Technology

11.2.4.  By Application

11.2.5.  By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Policy & Regulatory Landscape

15.  United States Economic Profile

16.  Competitive Landscape

16.1.              Thermo Fischer Scientific, Inc.

16.2.              Guardant Health, Inc.

16.3.              Biocept, Inc.

16.4.              Roche Diagnostics Corporation

16.5.              Myriad Genetics, Inc.

16.6.              Exact Sciences Corporation

16.7.              Illumina, Inc.

16.8.              Bio-Rad Laboratories, Inc.

16.9.              Biocept, Inc.

16.10.            NeoGenomics, Inc.

16.11.            Vortex Biosciences, Inc.

16.12.            Exosome Diagnostics, Inc.

16.13.            Agena Bioscience, Inc.

16.14.            MedGenome Inc.

16.15.            Personal Genome Diagnostics, Inc.

17.  Strategic Recommendations

18.  About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]